The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Congrats on a nice quarter. Maybe to start, I wanted to spend some time on the peripheral thrombectomy line, particularly Flash. You gave a couple
of numbers in there, but really, the question is 2-part. One, how are you thinking about the adoption of Flash relative to market expansion versus
share gains? And how can we think about Flash's impact in terms of the updated guidance range? How much of it was from Flash and the upcoming
arterial product launch versus neuro?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 02, 2023 / 8:30PM, PEN.N - Q1 2023 Penumbra Inc Earnings Call
Question: Robert Justin Marcus - JPMorgan Chase & Co, Research Division - Analyst
: Really helpful. If I could sneak one more in. This was probably the best stroke or neuro quarter you've had in a really long time. Just any -- how
sustainable is this and? Any onetime items to call out there?
Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst
: Just a couple of things. One, at this point in the launch, do you think that you've gotten Lightning Flash and Bolt to all the accounts? So I think on
the last call, you're still kind of in the LMR on Bolt. And then kind of a follow-up to that is, are you seeing an acceleration of the Bolt launch or benefit?
Because I think we talked about going to the VAC committees with both products at the same time. Just trying to figure out where you are in the
launch at this point.
Question: William John Plovanic - Canaccord Genuity Corp., Research Division - Analyst
: Great. And if I could, on the real product, given your recently announced agreement with the VA for real, how should we think about the revenue
contribution both near term and longer term from this product? Does it -- should we kind of bring it back into the discussion or still hold off maybe
until next year to start really thinking about it?
|
